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Signiﬁcantly enhanced proteolytic activity of
cyclen complexes by monoalkylation†
Chrischani Perera-Bobusch,a Jan Hormann,a Christoph Weise,b
Stefanie Wedepohl,c,d Jens Dernedded and Nora Kulak*a
A simple approach towards eﬃcient artiﬁcial proteases based on
the cyclen ligand is presented. We thus achieved an increase of the
proteolytic activity of two orders of magnitude when compared to
the unsubstituted cyclen complex. Amphiphilic Cu(II) and Co(III)
complexes cut BSA and myoglobin as model substrates at µM con-
centrations. MALDI-ToF MS is used to identify the cleavage
fragments.
The selective cleavage of proteins has numerous possible
applications, e.g. in proteomics, for industrial applications or
in medicinal chemistry for the degradation of pathogenic
proteins.1–3 Misfolded proteins play a key role in amyloido-
genic diseases like Alzheimer’s disease, Parkinson’s disease
and type 2 diabetes mellitus.4 They aggregate to form soluble
and insoluble oligomers, protofibrils and finally fibrils, which
constitute the so-called plaques. With population aging and
the subsequent rising numbers of patients suﬀering from
those maladies, artificial proteases are of growing scientific
and medicinal interest.3,5 Organic compounds and metal com-
plexes have already been developed for this purpose.6–8
Metal complexes exhibit the advantage of performing
diﬀerent steps of the hydrolysis reaction on their own (e.g.
polarization of the carbonyl group, nucleophilic attack at the
amide group, stabilization of tetrahedral intermediates), in
contrast the interaction of multiple functionalities would be
necessary for organic residues.9,10 For the specific cleavage of
proteins and peptides with metal complexes several examples
have been reported in literature.11–13 Seminal work was pub-
lished by Suh et al. who were able to drastically increase the
cleavage activity of the known artificial protease Cu(II) cyclen
(1,4,7,10-tetraazacyclododecane) by linkage to polystyrene and
introduction of an aldehyde group in proximity to the
macrocycle.14,15
Already more than 20 years ago, the mechanism for hydro-
lytic cleavage of unactivated amide bonds by Co(III) cyclen com-
plexes16 as well as the cleavage of Cu(II) tacn (1,4,7-
triazacyclononane) towards dipeptides and proteins was
reported.13 Such hydrolytic reactions are based on the Lewis
acidity of the metal center and the formation of a hydroxide
nucleophile from coordinated aqua ligands like in [M(cyclen)
(H2O)(OH)]
+/2+. This mechanistic proposal was recently corro-
borated for several metal ions (Co(III), Cu(II), Ni(II), Cd(II), Zn(II),
Pd(II)) by DFT calculations.10
Our goal was to increase the cleavage activity of Cu(II) and
Co(III) cyclen complexes through micelle formation via self-
assembly. A similar approach has already been shown to
promote DNA cleavage with Zn(II) cyclen derivatives.17 Also,
Zn(II) cyclen complexes with long alkyl chain substituents have
been investigated before for the cleavage of activated esters
like 4-nitrophenyl acetate in co-micellar solution with the sur-
factant Triton X-100.18 However, the application to proteins
has not been reported before. This is surprising, since the clea-
vage of proteins and peptides is of potential medicinal interest
and straightforward methods like gel electrophoresis and
MALDI-ToF MS can be used for monitoring such cleavage
reactions.
The self-assembly of the metal complexes of amphiphilic
cyclen derivatives is supposed to increase the local density of
catalytic units for protein cleavage. This approach can be com-
pared with the linkage of hydrophilic compounds to poly-
styrene and therefore might increase the cleavage activity of
cyclen complexes similarly.
We synthesized monosubstituted ligands with alkyl chains
of 10, 12 and 16 carbon atoms to investigate the influence of
the chain length on the cleavage activity. Among the many
protocols available for monofunctionalization of cyclen19 (see
ref. 4 and 5 therein for an overview), we have decided for a
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facile one-step procedure: Cyclen was applied in a fourfold
excess with the corresponding alkyl bromide and triethylamine
as base (cf. ESI, S-1.1†).20,21
We were able to isolate crystalline Cu(II) and Co(III) com-
plexes of L3 (Scheme 1). However, X-ray crystallography did not
provide molecular structures with satisfactory resolution due
to the floppiness of the long alkyl chain. For complexation
Cu(ClO4)2·6H2O was employed, whereas for the Co(III) com-
plex Na3[Co(CO3)3]·3H2O was used as a precursor (cf. ESI,
S-1.2†).22
For cleavage activity studies towards proteins the complexes
were generated in situ with Cu(NO3)2 and CoCl2, respectively,
with a 5% excess of the ligand if not stated otherwise (cf. ESI,
S-1.2†). Thus we were able to ensure that cleavage is induced
by the complex and not by free metal ions. Oxidation of the
Co(II) to the Co(III) metal center of cyclen complexes was
accomplished by exposing the solution to air.
The proteolytic activity was examined via SDS-PAGE (cf. ESI,
S-2.1†). BSA and myoglobin were applied as model proteins.
Protein cleavage was observable in the fading of the protein
bands upon addition of the complexes compared to the
untreated reference protein.
All six complexes, namely the Cu(II) and Co(III) cyclen com-
plexes of all three chain lengths, exhibit a remarkable cleavage
activity (Fig. 1, S-1†). The three Cu(II) complexes reveal a clea-
vage activity towards BSA more than two orders of magnitude
higher compared to the parent compound Cu(II) cyclen. For
Cu(II) cyclen there is barely any activity observable at a concen-
tration of 15 mM (Fig. S-2†), whereas for Cu(II) L3 the substrate
protein is already fully cleaved at a concentration of 0.05 mM.
We could observe an increase of the proteolytic activity with
increased length of the alkyl chain (Fig. 1). This is obvious for
L1 and L2 in the presence of both metals, however the diﬀer-
ence of L2 to L3 is hardly noticeable. For Co(III) L1 the protein
is fully cleaved at a concentration of 0.5 mM, whereas for the
corresponding L2 and L3 complexes full cleavage is already
achieved at a complex concentration of 0.05 mM. The cleavage
activity of the Co(III) complexes is slightly higher compared to
the Cu(II) complexes (cf. ESI, Fig. S-1†). With respect to poten-
tial in vivo applications, Co(III) complexes would be preferable
because of their exchange inertness.23
Since hydrolytic cleavage of biomolecules using Zn(II) is ubi-
quitous in nature (e.g. in the endonuclease S1 and the endo-
peptidase thermolysin) and is often reported in the field of
bioinorganic model chemistry (for DNA and RNA cleavage,24
however, interestingly only rarely seen for protein cleavage25),
we have also tested Zn(II) L3 (cf. ESI, Fig. S-9†). This complex
has shown similar activity like the Cu(II) and Co(III) analogs corro-
borating the above mentioned hydrolytic cleavage mechanism.10
In addition, catalytic activity of the Cu(II) and Co(III) complexes in
the absence of any reducing agent (like ascorbate, thiols or
H2O2), which is decisive for the activation of redoxactive metal
ions and subsequent generation of reactive oxygen species (ROS),
gives further indication to a hydrolytic mechanism.26
A comparison of the complexes formed in situ with the
isolated complexes of L3 showed the same cleavage activity.
Therefore we could ensure that the cleavage originates
indeed from the complexes (Fig. S-3†). Another concern
regarding the identity of the active cleavage agent, refers to
the involvement of Tris buﬀer molecules, which are also
potential ligands for Cu(II) and Co(III). Thus, Tris and MOPS,
the latter being a non-coordinating buﬀer, were exemplarily
compared for the cleavage reaction catalyzed by Cu(II) L3
(Fig. S-10†). The cleavage was slightly better in Tris buﬀer.
When the stability constants for Cu(II) cyclen (23.3 27) and Cu
(II) Tris (around 6 28) and the concentration ranges used
(0.1–1 mM vs. 50 mM) are considered, however, one can
exclude formation of any Cu(II) Tris species.
To make sure that the complexes do not cleave BSA exclu-
sively, myoglobin was applied as a second substrate. For the
Co(III) complex of L3 the cleavage activity towards myoglobin
was comparable to BSA but for the respective Cu(II) complex
complete cleavage was only observable at the lowest complex
concentrations (0.01 mM) applied (Fig. S-4†). With increasing
protease concentration the proteolytic activity surprisingly
decreased. This indicates that in case of the heme-containing
protein myoglobin high Cu(II) concentrations lead to some
kind of side reaction inhibiting the actual cleavage process.
Investigations elucidating this eﬀect with heme and non-heme
proteins are underway.
At physiological pH and temperature cleavage towards BSA
was still observable but markedly decreased (Fig. S-5†) in com-
parison to the conditions otherwise applied (pH 9, 50 °C).
Scheme 1 Synthesis of monoalkylated cyclen complexes ML (M =
Cu(II), Co(III), L = L1–L3).
Fig. 1 SDS-PAGE of BSA (0.75 µM) with monoalkylated Co(III) cyclen
complexes (concentrations in the ﬁgure are given in mM) with decyl-,
dodecyl- and hexadecylcyclen ligands L1–L3, respectively, from top to
bottom. Incubation at pH 9 and 50 °C for 48 h.
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Elevation of pH and temperature have been proven necessary
for other artificial proteases as well.15,29,30
A time-dependent study with BSA revealed that for Co(III) L3
only 16 h of incubation were necessary for complete cleavage
at 0.05 mM, whereas 39 h were necessary for Cu(II) L3
(Fig. S-6†). After 4 h of incubation just a very faint protein
band was detectable on the gel for both complexes but the
total cleavage of the protein took 4 and 10 times longer,
respectively. This proteolytic activity is comparable to that of
other artificial proteases of even more complex structures.14,29
Analyses by SDS-PAGE performed with metal salts corres-
ponding to the in situ generated complexes substantiated that
the substrate cleavage originates from the synthesized com-
plexes and could not be ascribed to free metal ions (Fig. S-7†).
CoCl2 showed no cleavage activity towards BSA at all, whereas
Cu(NO3)2 induced only very weak cleavage. Those results
clearly indicate that the observed cleavage originates from the
cyclen complexes.
For the above described SDS-PAGE experiments a Tris-
glycine buﬀer system was used, which is suitable for the detec-
tion of proteins >30 kDa. In order to estimate the size of the
myoglobin fragments, however, the Tris-tricine buﬀer system
was applied since this system is more suitable for low-mole-
cular mass proteins and peptides (1–30 kDa).31 The size of the
myoglobin fragments was thus estimated to be in a range of
4–7 kDa (Fig. S-8†).31 To further characterize these fragments
MALDI-ToF MS was performed. The spectrum showed frag-
ments between 4.0 and 7.2 kDa (Fig. 2). Fragments with a
similar size have already been reported, in particular the frag-
ment 93–154, the N terminus of which is close to the heme
moiety (proximal His94), has been previously identified by
Suh et al.15
In order to evaluate the cytotoxicity of the complexes, the
MTT assay was applied for the Cu(II) and Co(III) complexes of
L2 in comparison to Cu(II) cyclen and Co(III) cyclen. In
Fig. S-11,† the dose–response relationship of these complexes
incubated for 48 h on A549 lung cancer cells is shown. The cal-
culated IC50 values for Cu(II) and Co(III) cyclen complexes were
both about 1.7 mM, 9.5 µM for Cu(II) L2 and 24.5 µM for Co(III)
L2. The exact mechanism of this enhanced cytotoxicity is not
known yet, but an interaction of the alkyl chains with the cell
membranes due to their composition of amphiphilic lipid
molecules is highly probable.32 Nevertheless, the IC50 values
are comparable to some approved drugs: at the same con-
ditions in A549 cells e.g. 64–70 µM for the anticancer drug cis-
platin and 2–3 µM for imatinib, a drug originally developed as
an anticancer drug but found to inhibit amyloid-β for-
mation.33,34 Curcumin (16 μM) and resveratrol (26 μM) have
been shown to deplete Aβ plaques.35–37
The structure–activity relationship of the amphiphilic metal
complexes was investigated with the established “pyrene 1 : 3
ratio” method (Fig. S-12 and Table S-2†). This technique uti-
lizes the change of the ratio of the first and third vibronic peak
(I1/I3) of fluorescing pyrene while changing its environment
from hydrophilic to hydrophobic due to micelle formation.38,39
Above the critical micellar concentration (cmc) pyrene is sup-
posed to be located in the hydrophobic core of the micelles
causing an increase of I3. The peak I3 could not be detected for
the complexes presented here and a drastic decrease of the
fluorescence intensity was observed below the cmc. This can
be explained with fluorescence quenching of pyrene which has
been described before for Cu(II) and Co(II/III) surfactant
systems.40,41 However, regarding the ratio of the intensity at
375 and 385 nm, values reported in the literature for I1 and I3,
a sigmoidal curve could be generated as expected for this
method (Fig. S-12†).42 The values for the cmc of the Cu(II) com-
plexes of L1–L3 and Co(III) L3 calculated from these measure-
ments can be taken from Table S-2.† The results indicate that
particle assembly requires complex concentrations above the
amount essential for complete protein cleavage. Therefore
micelle formation can be ruled out as the origin of the
improved cleavage activity but an alternative method for the
determination of the cmc should be utilized to verify the
values presented here. One might expect discrepancies of the
two experiments due to temperature diﬀerences (50 °C (323 K)
for the cleavage experiments and only 25 °C (298 K) for the
cmc determination). For cationic amphiphiles it was found,
however, that the cmc is almost constant over a wide range of
temperature, e.g. hexamethyltrimethylammonium bromide
(cmc around 0.02–0.04 mM in a range of 280 to 360 K).43
A possible explanation for the improved proteolytic activity
might rather be the attraction of the alkyl chains to the hydro-
phobic domains of the target proteins, which would facilitate
the attack of the catalytic unit. The dependence of the proteo-
lytic activity on the alkyl chain length – the longer the chain,
i.e. the more hydrophobic the molecule, the higher the clea-
vage activity – is also a hint in this direction. Indeed, BSA exhi-
bits a hydrophobic region, subdomain IIA, and the heme
moiety of myglobin is known to be located in a hydrophobic
pocket.44,45 Computational studies have revealed oxygenated
myoglobin as a transporter and sequestering agent for fatty
Fig. 2 MALDI-ToF MS of a myoglobin sample (2.25 µM) treated with
Cu(II) L3 (10 µM, bottom) vs. an untreated sample (top) (50 mM Tris-HCl
pH 7.4, 50 °C, 48 h). Average masses and amino acid positions of the
fragments are given; numbering refers to the database entry SwissProt
P68082 for horse myoglobin.
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acids in muscles with the hydrophobic heme pocket being the
binding site. The hydrophobic tail of the fatty acids is located
within the pocket lined with hydrophobic amino acids
whereas the hydrophilic head group interacts with two Lys
amino acids.46 Along the lines of these findings the cuts of the
amphiphilic cyclen complexes in myoglobin close to the heme
moiety can be conclusively explained. Molecular modelling
studies are underway to prove this hypothesis.
Conclusions
In only two steps alkylated Cu(II) and Co(III) cyclen complexes
were obtained, which were shown to act as eﬃcient artificial
proteases. Compared to other artificial proteases this simple
system can keep up with far more complex structures regard-
ing their proteolytic activity.14,29 With SDS-PAGE cleavage of
BSA and myoglobin as model proteins could be shown by the
intensity loss of the protein bands, whereas MALDI-ToF MS
allowed to identify cleavage sites for myoglobin. The cyto-
toxicity of the novel complexes was comparable to other drugs
discussed for the treatment of e.g. Alzheimer’s disease, a long-
term goal for the presented complexes due to their conceivable
interactions with disease-related Aβ peptides. Hydrophobic
interactions with the proteins to be cleaved probably account
for the high cleavage activity, rather than micelle formation of
the amphiphilic complexes.
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